Clinical development of targeted and immune based anti-cancer therapies
NA Seebacher, AE Stacy, GM Porter… - Journal of Experimental & …, 2019 - Springer
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
Management of brain metastases in non–small-cell lung cancer
V Ernani, TE Stinchcombe - Journal of oncology practice, 2019 - ascopubs.org
Lung cancer is the leading cause of cancer-related death in the United States.
Approximately 20% of these patients present with brain metastases (BMs). Surgical …
Approximately 20% of these patients present with brain metastases (BMs). Surgical …
Targeting the complement pathway as a therapeutic strategy in lung cancer
EK Kleczko, JW Kwak, EL Schenk… - Frontiers in …, 2019 - frontiersin.org
Lung cancer is the leading cause of cancer death in men and women. Lung
adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances …
adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances …
[HTML][HTML] Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases
JJ Lin, GY Jiang, N Joshipura, J Ackil… - Journal of Thoracic …, 2019 - Elsevier
Background Central nervous system (CNS) metastases represent a significant source of
morbidity and mortality for patients with ALK tyrosine kinase gene (ALK)-positive NSCLC …
morbidity and mortality for patients with ALK tyrosine kinase gene (ALK)-positive NSCLC …
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
H Hou, D Sun, K Liu, M Jiang, D Liu, J Zhu… - Cancer Management …, 2019 - Taylor & Francis
Background: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have
anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK …
anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK …
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein rearranged
in 2–7% of non-small cell lung cancer (NSCLC) cases. This gene has become the second …
in 2–7% of non-small cell lung cancer (NSCLC) cases. This gene has become the second …
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review
Introduction Oral tyrosine kinase inhibitors targeting the chromosomal rearrangements of the
anaplastic lymphoma kinase gene (ALK) in non-small cell lung cancer (NSCLC) were …
anaplastic lymphoma kinase gene (ALK) in non-small cell lung cancer (NSCLC) were …
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis
Introduction We evaluated the incidence of pneumonitis in clinical trials of anaplastic
lymphoma kinase (ALK) inhibitors in patients with advanced non-small cell lung cancer …
lymphoma kinase (ALK) inhibitors in patients with advanced non-small cell lung cancer …
Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
P Song, F Zhang, Y Li, G Yang, W Li, J Ying… - Cancer …, 2019 - Wiley Online Library
Background TP53 mutations are the most prevalent mutations detected in non‐small‐cell
lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of …
lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of …